Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PLAU encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. Additionally we are shipping PLAU Kits (88) and PLAU Proteins (58) and many more products for this protein.
Showing 10 out of 334 products:
Human Polyclonal PLAU Primary Antibody for EIA, IHC (p) - ABIN360681
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 5 references for ABIN360681
Human Polyclonal PLAU Primary Antibody for IHC (p), ELISA - ABIN360680
Sperl, Jacob, Arroyo de Prada, Stürzebecher, Wilhelm, Bode, Magdolen, Huber, Moroder: (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. in Proceedings of the National Academy of Sciences of the United States of America 2000
Show all 5 references for ABIN360680
Human Monoclonal PLAU Primary Antibody for DB, EIA - ABIN1109451
Bashkov, Stepanova, Domogatsky: Collagen-targeted antibodies inhibit platelet-dependent thrombosis in vivo. in Thrombosis research 1994
Show all 2 references for ABIN1109451
Human Monoclonal PLAU Primary Antibody for ELISA (Capture), EIA - ABIN112281
Plas, Carroll, Jilch, Mihaly, Vesely, Ulrich, Pflüger, Binder: Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. in International journal of cancer. Journal international du cancer 1998
Human Polyclonal PLAU Primary Antibody for ELISA, WB - ABIN185470
Morgan, Hill: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. in Cancer cell international 2005
Transplantation of uPA (show PRAP1 Antibodies) gene modified mesenchymal stem cells suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis
ApaL1 and Taq1 single nucleotide polymorphisms of the urokinase and VDR (show CYP27B1 Antibodies) genes are associated with recurrent urolithiasis in a Caucasian population.
1,25D3 works as a modifier of NF-kappaB (show NFKB1 Antibodies)/GPX1 (show GPX1 Antibodies)/uPA (show PRAP1 Antibodies) expression, inhibiting cisplatin-resistance and cell invasive ability of salivary adenoid cystic carcinoma cells
Resveratrol inhibited hypoxia-induced HIF-1alpha (show HIF1A Antibodies) protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA (show PRAP1 Antibodies) and MMP2 (show MMP2 Antibodies).
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
These findings strongly support the use of uPA (show PRAP1 Antibodies)/PAI-1 (show SERPINE1 Antibodies) together with clinic-pathological parameters as an evidence-based, clinically relevant and inexpensive decision tool in the routine of a breast center.
Data suggest that enhanced levels of uPA (show PRAP1 Antibodies) in breast cancer modulate the mitogenic effects of EGF (show EGF Antibodies) which helps to better understand breast cancer pathogenesis.
Results found high levels of uPA (show PRAP1 Antibodies) and uPAR (show PLAUR Antibodies) exclusively in metastatic osteosarcoma (OS)cells and suggest that malignant conversion of OS cells to uPA (show PRAP1 Antibodies)/uPAR (show PLAUR Antibodies) axis in an autocrine and paracrine fashion.
The morphologically normal tissue adjacent to the tumor shows the substantial expression of MMP-2 (show MMP2 Antibodies) and MMP-9 (show MMP9 Antibodies) and in some cases the enhanced activity of uPA (show PRAP1 Antibodies) and ACE (show ACE Antibodies), which makes an additional contribution to the increased invasive potential of tumor
Crystal structure of uPA (show PRAP1 Antibodies) bound with cyclic peptidic inhibitors.
GM-CSF (show CSF2 Antibodies) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (show PLAUR Antibodies))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.
Study shows that the competitive expression or activity of tPA (show PLAT Antibodies) and/or PAI-1 (show SERPINE1 Antibodies), rather than an altered uPA expression, determines the plasmin (show PLG Antibodies)-mediated Abeta (show APP Antibodies) proteolysis in brains affected by Alzheimer's disease
Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA.
beta-elemene downregulates expression of uPA, uPAR (show PLAUR Antibodies), MMP-2 (show MMP2 Antibodies), and MMP-9 (show MMP9 Antibodies) in a murine intraocular melanoma model
Data indicate that closed head trauma sequentially releases tissue-type plasminogen activator (tPA (show PLAT Antibodies)) followed by delayed synthesis and release of urokinase plasminogen (show PLG Antibodies) activator (uPA) from injured brain.
Binding of urokinase to urokinase plasminogen activator receptor (show PLAUR Antibodies) promotes dendritic spine recovery and functional outcome after ischemic stroke.
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (show PLAUR Antibodies)) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR (show PLAUR Antibodies) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (show PLAUR Antibodies) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen (show PLG Antibodies) activator/plasmin (show PLG Antibodies) system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 (show SERPINE2 Antibodies) production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein